Summary of COVID-19 zansecimab studies

1. Jones et al., Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19

95 patient zansecimab late treatment RCT: 36% higher mortality (p=0.58) and 70% higher combined mortality/intubation (p=0.28).
RCT 95 hospitalized patients with COVID-19 pneumonia showing no significant differences with zansecimab (LY3127804, anti-Angiopoietin-2 antibody).
Jan 2022, Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, https://journals.sagepub.com/doi/10.1177/11795484221119316, https://c19p.org/jones2